However, our study demonstrates that in the era of IMiDs, PIs, and anti‐CD38 mAb, survival patterns of t(11;14) MM appear inferior to standard‐risk MM and may mirror that of the high‐risk cohort. This evidence concerns the gene CD38 and Miyoshi myopathy.